Waldenstrom macroglobulinemia

Common Name(s)

Waldenstrom macroglobulinemia

Waldenstrom macroglobulinemia is a chronic, slow-growing lymphoproliferative disorder. It usually affects older adults and is primarily found in the bone marrow, although lymph nodes and the spleen may be involved. Affected individuals have a high level of an antibody called immunoglobulin M (IgM) in their blood, which can cause thickening of the blood (hyperviscosity). Although some individuals initially do not have symptoms and are diagnosed from routine blood work, common symptoms may include weakness, appetite loss and weight loss. Other symptoms may include peripheral neuropathy, fever, Raynaud's phenomenon, and mental status changes. Hyperviscosity of the blood may cause nosebleeds, headaches, dizziness, and blurring or loss of vision. The cause of the condition is not known but environmental, genetic, and viral factors have been suggested. There have been some reports of familial cases suggesting a genetic predisposition. Treatment is often reserved for those with symptoms and may include various medications including corticosteroids, alkylating agents, biologic response modifiers and purine analogues.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Waldenstrom macroglobulinemia" for support, advocacy or research.

International Waldenstrom's Macroglobulinemia Foundation

To offer mutual support and encouragement to the Waldenstrom's macroglobulinemia community and others with an interest in the disease. To provide information and educational programs that address patients' concerns. To promote and support research leading to better treatments and ultimately a cure.

Last Updated: 16 Jul 2014

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Waldenstrom macroglobulinemia" for support, advocacy or research.

International Waldenstrom's Macroglobulinemia Foundation

To offer mutual support and encouragement to the Waldenstrom's macroglobulinemia community and others with an interest in the disease. To provide information and educational programs that address patients' concerns. To promote and support research leading to better treatments and ultimately a cure.

http://www.iwmf.com

Last Updated: 16 Jul 2014

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Waldenstrom macroglobulinemia" returned 125 free, full-text research articles on human participants. First 3 results:

A novel MYD88 mutation, L265RPP, in Waldenström macroglobulinemia activates the NF-κB pathway to upregulate Bcl-xL expression and enhances cell survival.
 

Author(s): T Nagao, G Oshikawa, S Ishida, H Akiyama, Y Umezawa, A Nogami, T Kurosu, O Miura

Journal:

 

Last Updated: 18 May 2015

Go To URL
The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenström macroglobulinemia.
 

Author(s): Magali Le Garff-Tavernier, Linda Herbi, Christophe de Romeuf, Nabih Azar, Damien Roos-Weil, Patrick Bonnemye, Rémi Urbain, Véronique Leblond, Hélène Merle-Beral, Vincent Vieillard

Journal: Haematologica. 2015 Apr;100(4):e147-51.

 

Last Updated: 1 Apr 2015

Go To URL
Extramedullary Waldenström macroglobulinemia.
 

Author(s): Ranjit Banwait, Yosra Aljawai, Joseph Cappuccio, Serena McDiarmid, Elizabeth A Morgan, Houry Leblebjian, Aldo M Roccaro, Jacob Laubach, Jorge J Castillo, Claudia Paba-Prada, Steven Treon, Robert Redd, Edie Weller, Irene M Ghobrial

Journal: Am. J. Hematol.. 2015 Feb;90(2):100-4.

 

Disease assessment in Waldenstrom Macroglobulinemia (WM) is dependent on the percent involvement of B-cell neoplasm in the bone marrow and IgM paraprotein in the serum. A subset of patients also demonstrates extramedullary involvement, which is infrequently examined. The role of extramedullary ...

Last Updated: 23 Jan 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Waldenstrom macroglobulinemia" returned 20 free, full-text review articles on human participants. First 3 results:

Waldenstrom macroglobulinemia: prognosis and management.
 

Author(s): A Oza, S V Rajkumar

Journal:

 

Waldenstrom macroglobulinemia (WM) is a B-cell lymphoplasmacytic lymphoma characterized by monoclonal immunoglobulin M protein in the serum and infiltration of bone marrow with lymphoplasmacytic cells. Asymptomatic patients can be observed without therapy. First-line therapy should ...

Last Updated: 30 Mar 2015

Go To URL
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
 

Author(s): Meletios A Dimopoulos, Efstathios Kastritis, Roger G Owen, Robert A Kyle, Ola Landgren, Enrica Morra, Xavier Leleu, Ramón García-Sanz, Nikhil Munshi, Kenneth C Anderson, Evangelos Terpos, Irene M Ghobrial, Pierre Morel, David Maloney, Mathias Rummel, Véronique Leblond, Ranjana H Advani, Morie A Gertz, Charalampia Kyriakou, Sheeba K Thomas, Bart Barlogie, Stephanie A Gregory, Eva Kimby, Giampaolo Merlini, Steven P Treon

Journal: Blood. 2014 Aug;124(9):1404-11.

 

Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of International Workshops on WM (IWWM). As ...

Last Updated: 29 Aug 2014

Go To URL
Novel treatment options for Waldenström macroglobulinemia.
 

Author(s): Houry Leblebjian, Amit Agarwal, Irene Ghobrial

Journal: Clin Lymphoma Myeloma Leuk. 2013 Sep;13 Suppl 2():S310-6.

 

Waldenström macroglobulinemia (WM), first described by Jan Waldenström in 1944, is a lymphoplasmacytic lymphoma characterized by the presence of an immunoglobulin M monoclonal gammopathy in the blood and monoclonal small lymphocytes and lymphoplasmacytoid cells in the bone marrow. ...

Last Updated: 2 Dec 2013

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma
 

Status: Recruiting

Condition Summary: Lymphoma; Lymphoplasmacytic Lymphoma; Waldenström Macroglobulinemia

 

Last Updated: 13 Nov 2015

Go to URL
Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
 

Status: Recruiting

Condition Summary: Waldenstrom's Macroglobulinemia

 

Last Updated: 27 Oct 2015

Go to URL
Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia
 

Status: Recruiting

Condition Summary: Waldenstrom's Macroglobulinemia

 

Last Updated: 27 Oct 2015

Go to URL